{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:57:23Z","timestamp":1753891043114,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>With the persisting low vaccination intake, particularly in children of low-and middle-income countries (LMICs), seroepidemiological studies are urgently needed to guide and tailor COVID-19 pandemic response efforts in schools and to put mitigation strategies in place for a future post-pandemic resurgence. However, there is limited data on SARS-CoV-2 infection-induced and vaccine-induced humoral immunity in schoolchildren in LMICs, including Ethiopia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>As the spike receptor binding domain (RBD) is the major target for neutralization antibodies and useful to predict the correlates of protection, we used an in-house anti-RBD IgG ELISA to assess and compare infection-induced antibody response at two-time points and BNT162b2 (BNT) vaccine-induced antibody response at a one-time point in schoolchildren in Hawassa, Ethiopia. In addition, we measured and compared the levels of binding IgA antibodies to spike RBD of SARS-CoV-2 Wild type, Delta, and Omicron variants in a small subset of unvaccinated and BNT-vaccinated schoolchildren.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>When we compare SARS-CoV-2 infection-induced seroprevalences among unvaccinated school children (7-19 years) at the two blood sampling points with a 5-month interval, we observed an over 10% increase, from 51.8% (219\/419) in the first week of December 2021 (post-Delta wave) to 67.4% (60\/89) by the end of May 2022 (post-Omicron wave). Additionally, we found a significant correlation (<jats:italic>p<\/jats:italic> = 0.001) between anti-RBD IgG seropositivity and a history of having COVID-19-like symptoms. Compared to the levels of SARS-CoV-2 infection-induced anti-RBD IgG antibodies before vaccination, higher levels of BNT vaccine-induced anti-RBD IgG antibodies were observed even in SARS-CoV-2 infection-na\u00efve schoolchildren of all age groups (<jats:italic>p<\/jats:italic> = 0.0001). Importantly, one dose of the BNT vaccine was shown to be adequate to elicit a strong antibody response in schoolchildren with pre-existing anti-RBD IgG antibodies comparable to that of SARS-CoV-2 infection-naive schoolchildren receiving two doses of BNT vaccine, suggesting a single dose administration of the BNT vaccine could be considered for schoolchildren who had prior SARS-CoV-2 infection when a shortage of vaccine supply is a limiting factor to administer two doses irrespective of their serostatus. Despite the small sample size of study participants, the BNT vaccine is shown to be immunogenic and safe for schoolchildren. Irrespective of schoolchildren\u2019s vaccination status, we observed a similar pattern of significantly higher levels of IgA antibodies to Delta-RBD than to Omicron-RBD (<jats:italic>p<\/jats:italic> &amp;lt; 0.001) in a randomly selected subset of schoolchildren, yet comparable to Wuhan-RBD, suggesting these schoolchildren were more likely to have had SARS-CoV-2 infection with Delta variant. Additionally, we noted a broader IgA antibody reactivity to SARS-CoV-2 variants in vaccinated schoolchildren with prior SARS-CoV-2 infection, supporting the superiority of hybrid immunity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our serological data indicate a significant increase in SARS-CoV-2 seroprevalence in children at a post-Omicron five-month follow-up compared to a post-Delta enrolment. Despite the small sample size of study participants, the BNT vaccine is shown to be immunogenic and safe for schoolchildren. Hybrid immunity would likely provide a broader humoral immunity against Wuhan strain, Delta, and Omicron variants than natural infection or vaccination alone does. However, future longitudinal cohort studies in SARS-CoV-2-na\u00efve and COVID-19-recovered schoolchildren receiving the BNT vaccine are needed for a better understanding of the kinetics, breadth, and durability of BNT vaccine-induced multivariant-cross reactive immunity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1163688","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T05:27:41Z","timestamp":1686806861000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia"],"prefix":"10.3389","volume":"14","author":[{"given":"Yared","family":"Merid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wondwosen","family":"Tekleselasie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emnet","family":"Tesfaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anteneh","family":"Gadisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dessalegn","family":"Fentahun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alegntaw","family":"Abate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aynalem","family":"Alemu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adane","family":"Mihret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andargachew","family":"Mulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tesfaye","family":"Gelanew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2020-320338","article-title":"Why is COVID-19 less severe in children? a review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections","volume":"106","author":"Zimmermann","year":"2021","journal-title":"Arch Dis Child"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.4573","article-title":"Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis","volume":"175","author":"Viner","year":"2021","journal-title":"JAMA Pediatrics"},{"key":"B3","unstructured":"Children and COVID-19: state-level data report"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(22)00060-8","article-title":"SARS-CoV-2 spread and hospitalisations in paediatric patients during the omicron surge","volume":"6","author":"Belay","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101786","article-title":"SARS-CoV-2 seroprevalence in children worldwide: a systematic review and meta-analysis","volume":"56","author":"Naeimi","year":"2023","journal-title":"eClinicalMedicine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after covid-19 vaccination and previous infection","author":"Hall","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamapediatrics.2020.4573","article-title":"Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults","volume":"175","author":"Viner","year":"2021","journal-title":"JAMA Pediatr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/vaccines10010011","article-title":"Adults\u2019 acceptance of COVID-19 vaccine for children in selected lower- and middle-income countries","volume":"10","author":"Bono","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B9","unstructured":"Pros and cons for schools reopening amid coronavirus concerns. study.com"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1002992","article-title":"Do we need to vaccinate every child against COVID-19: what evidence suggests\u2013a systematic review of opinions","volume":"10","author":"Paul","year":"2022","journal-title":"Front Public Health"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1094727","article-title":"The BNT162b2 vaccine induces humoral and cellular immune memory to SARS-CoV-2 wuhan strain and the omicron variant in children 5 to 11 years of age","volume":"13","author":"Cinicola","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202826","article-title":"BNT162b2 protection against the omicron variant in children and adolescents","volume":"386","author":"Price","year":"2022","journal-title":"New Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/vaccines9101102","article-title":"Safety, immunogenicity, and efficacy of COVID-19 vaccines in children and adolescents: a systematic review","volume":"9","author":"Lv","year":"2021","journal-title":"Vaccines (Basel)"},{"volume-title":"COVID-19 vaccines: AU, Africa CDC and COVAX call on donors and manufacturers to accelerate access | Africa renewal","year":"","key":"B14"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-095916","article-title":"Broadly neutralizing antiviral antibodies","volume":"31","author":"Corti","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03165-22","article-title":"RBD-based ELISA and luminex predict anti-SARS-CoV-2 surrogate-neutralizing activity in two longitudinal cohorts of German and Spanish health care workers","author":"Aguilar","year":"2023","journal-title":"Microbiol Spectr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3390\/vaccines10060859","article-title":"A single dose of ChAdOx1 nCoV-19 vaccine elicits high antibody responses in individuals with prior SARS-CoV-2 infection comparable to that of two-Dose-Vaccinated, SARS-CoV-2-Infection-Na\u00efve individuals: a longitudinal study in Ethiopian health workers","volume":"10","author":"Gelanew","year":"2022","journal-title":"Vaccines"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/v13030422","article-title":"Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection","volume":"13","author":"Gobbi","year":"2021","journal-title":"Viruses"},{"key":"B19","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3390\/genes14030705","article-title":"Molecular epidemiology and diversity of SARS-CoV-2 in Ethiopia, 2020\u20132022","volume":"14","author":"Sisay","year":"2023","journal-title":"Genes"},{"key":"B20","doi-asserted-by":"publisher","first-page":"22640","DOI":"10.1038\/s41598-021-02097-2","article-title":"Saliva is superior over nasopharyngeal swabs for detecting SARS-CoV2 in COVID-19 patients","volume":"11","author":"Beyene","year":"2021","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV [[\/amp]]mdash; a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-022-07247-z","article-title":"High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers","volume":"22","author":"Gelanew","year":"2022","journal-title":"BMC Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0000611","article-title":"COVID-19 vaccine hesitancy and its determinants among sub-Saharan African adolescents","volume":"2","author":"Wang","year":"2022","journal-title":"PloS Global Public Health"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.35975","article-title":"Seroprevalence of SARS-CoV-2 antibodies among children in school and day care in Montreal, Canada","volume":"4","author":"Zinszer","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/vaccines10010064","article-title":"Large-Scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection","volume":"10","author":"Israel","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory b cell responses in SARS-CoV-2 na\u00efve and recovered individuals following mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2204336119","article-title":"The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2","volume":"119","author":"Townsend","year":"2022","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1056525","article-title":"Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity","volume":"14","author":"Henze","year":"2023","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.21921","article-title":"Immunogenicity of extended mRNA SARS-CoV-2 vaccine dosing intervals","volume":"327","author":"Grunau","year":"2022","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01126-6","article-title":"Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses","volume":"23","author":"Hall","year":"2022","journal-title":"Nat Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1016\/j.cell.2021.10.011","article-title":"Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine","volume":"184","author":"Payne","year":"2021","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.chom.2021.12.004","article-title":"Strong humoral immune responses against SARS-CoV-2 spike after BNT162b2 mRNA vaccination with a 16-week interval between doses","volume":"30","author":"Tauzin","year":"2022","journal-title":"Cell Host Microbe"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00863-2","article-title":"SARS-CoV-2 omicron RBD shows weaker binding affinity than the currently dominant delta variant to human ACE2","volume":"7","author":"Wu","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"100603","DOI":"10.1016\/j.xcrm.2022.100603","article-title":"Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination","volume":"3","author":"Mantus","year":"2022","journal-title":"Cell Rep Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"9950","DOI":"10.1038\/s41598-022-13495-5","article-title":"Long-COVID in children and adolescents: a systematic review and meta-analyses","volume":"12","author":"Lopez-Leon","year":"2022","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00266-4","article-title":"WHO international standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community","volume":"3","author":"Knezevic","year":"2022","journal-title":"Lancet Microbe"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1163688\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T05:27:45Z","timestamp":1686806865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1163688\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2023.1163688"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1163688","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"article-number":"1163688"}}